NCT06096077 is a clinical trial in Angioedema, sponsored by Methodist Health System.

Who is sponsoring NCT06096077?

NCT06096077 is sponsored by Methodist Health System.

What condition does NCT06096077 study?

NCT06096077 studies Angioedema.

Is NCT06096077 still recruiting?

NCT06096077 is currently completed. Last updated 18 January 2024.

Last reviewed 2024-01-18 · How we verify

NCT06096077

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Tranexamic Acid for Angiotensin-converting Enzyme Inhibitor-induced Angioedema in the Emergency Department

Completed Last updated 18 January 2024

What this trial tests

trial in Angioedema in 50 participants. Completed in 23 August 2023.

Timeline

30 November 2022

Primary endpoint
23 August 2023

23 August 2023

Quick facts

Lead sponsor	Methodist Health System
Status	Completed
Study type	OBSERVATIONAL
Enrollment	50
Start date	30 November 2022
Primary completion	23 August 2023
Estimated completion	23 August 2023
Sites	1 location across United States

Conditions studied

Angioedema — all drugs for Angioedema →

Sponsor

Methodist Health System — full company profile →

Who can join

Adults 18 to 75, any sex, with Angioedema. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Angiotensin-converting enzyme inhibitor ACEi induced angioedema ACEi-AE is defined as physical swelling of the deep skin layers or mucous membranes due to increased vascular permeability and leakage of fluid into the interstitial space caused while taking an ACEi

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Angioedema

Currently open trials in the same condition.

NCT07046806 — Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients · Phase 1, PHASE2 · recruiting
NCT06818474 — Lanadelumab in Long-term Prophylaxis of Acquired Angioedema · Phase 4 · recruiting

Other Methodist Health System trials

Trials by the same sponsor.

NCT06698302 — Validation of COMPAT-SF Spanish Translation · recruiting
NCT04090034 — Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors · recruiting
NCT07486362 — Evaluation of Emergency Medicine Pharmacist Impact on Blood Culture Review Following Emergency Department Discharge · recruiting
NCT06222424 — Emergency Medicine Pharmacist Prescriptive Authority for Resolution of Outpatient Prescription Issues · NA · completed
NCT07492758 — Management of Extremity Injuries Registry · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06096077 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Methodist Health System
Last refreshed: 18 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06096077.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing